Physician profile
Steven Frank
NPI 1932219516
$14,545.70
in general payments reported to CMS, 2019-2025
44 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,713 · 2020: $1,157 · 2021: $2,199 · 2022: $1,948 · 2023: $2,590 · 2024: $2,379 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,529.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,383.92 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,662.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,195.84 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $1,165.10 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $936.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $763.95 | 2019-2022 | |
| Abbvie INC. | $659.86 | 2021-2025 | |
| Abbott Laboratories | $631.36 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $562.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $514.46 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $462.55 | 2023-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $402.10 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $309.45 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $293.91 | 2019-2021 | |
| Allergan, INC. | $240.73 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.